Mereo BioPharma Group plc
MREO
$2.74
$0.2811.38%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 7.27M | 6.45M | 6.20M | 7.87M | 5.91M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.02M | 14.70M | 9.15M | 12.45M | 9.42M |
| Operating Income | -11.02M | -14.70M | -9.15M | -12.45M | -9.42M |
| Income Before Tax | -12.89M | -7.05M | -15.00M | -12.26M | -8.95M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -12.89M | -7.05M | -15.00M | -12.26M | -8.95M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.89M | -7.05M | -15.00M | -12.26M | -8.95M |
| EBIT | -11.02M | -14.70M | -9.15M | -12.45M | -9.42M |
| EBITDA | -10.87M | -14.55M | -8.99M | -12.31M | -9.27M |
| EPS Basic | -0.41 | -0.23 | -0.49 | -0.43 | -0.32 |
| Normalized Basic EPS | -0.05 | -0.03 | -0.06 | -0.05 | -0.04 |
| EPS Diluted | -0.41 | -0.23 | -0.49 | -0.43 | -0.32 |
| Normalized Diluted EPS | -0.05 | -0.03 | -0.06 | -0.05 | -0.04 |
| Average Basic Shares Outstanding | 156.86M | 155.01M | 154.03M | 142.35M | 140.05M |
| Average Diluted Shares Outstanding | 31.37M | 31.00M | 30.81M | 28.47M | 28.01M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |